List the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation
|
|
- Georgina O’Brien’
- 6 years ago
- Views:
Transcription
1
2 Alere (honoraria)
3 List the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation testing algorithm Interpret challenging HIV screening results Recall the role of molecular testing in the diagnosis and management of HIV
4 30 year old pregnant female admitted to Labor and Delivery Found to be in early stages of labor Upon questioning, it was revealed that the patient did not receive routine prenatal care Several laboratory tests were ordered, including a rapid HIV antibody test Rapid HIV test was found to be positive
5 Follow-up fourth generation HIV antigen/antibody test performed Negative Does this patient have HIV? What follow-up testing would you recommend? Would you have tested this patient differently?
6 Enveloped single stranded RNA retrovirus HIV-1 Responsible for AIDS worldwide pandemic Groups M (major), O (outlier), and N (non- M, non-o) Derived from chimpanzees HIV-2 Limited geographic distribution (Africa and parts of Europe) Subgroups A-G Derived from sooty mangabeys
7 Commonly transmitted sexually through direct contact with body fluids including blood, semen, and vaginal secretions Tropism for CD4+ T cells and macrophages Three clinical stages of HIV infection Acute HIV infection- associated with non-specific symptoms (fever, rash, malaise, lymphadenopathy, and pharyngitis) Clinical latency- symptom free period with low level viral replication AIDS- marked by increased viral load, decrease in CD4 positive T lymphocyte, and resultant opportunistic infections
8 RNA P24 Antigen Diagnosis may be missed if inappropriate test is used Antibody Infection Days Eclipse Period Acute Retroviral Syndrome (symptomatic and very contagious) Adapted from Laboratory Testing Recommendations for the Diagnosis of HIV, Updated Recommendations, Centers of Disease Control and prevention, June 2014 Clinical Latency (asymptomatic)
9 First Generation Third Generation Viral lysate antigen target Detect IgG only Only ~95% specific 8-10 week window Recombinant antigen target Detect IgG and IgM 99.5% specific 2-3 week window Second Generation Fourth Generation Recombinant antigen target Detect IgG only 99% specific 4-6 week window Recombinant antigen target Detect p24 antigen Detect IgG and IgM 99.5% specific 2 week window Adapted from: Chappel R J, Wilson K M, Dax E M, Immunoassays for the Diagnosis of HIV: Meeting Future Needs by Enhancing the Quality of Testing, Future Microbiol. 2009;4(8):
10 HIV RNA Detectable ~10 Days Following Infection HIV Antibodies Detectable ~20 Days Following Infection HIV Antigen Detectable ~15 Days Following Infection HIV Antibody Response Expands Nucleic Acid Detection Test Positive Fourth Generation Antibody/Antigen Assay Positive Third Generation Antibody Assay Positive Western Blot Positive
11 Traditional screening performed using a third generation enzyme immunoassay (EIA) Traditional confirmation performed by Western blot immunoassay Discerns antibody specificity to immobilized HIV proteins Must have antibodies to multiple key proteins to be interpreted as positive Novel fourth generation assays detect both antibody and p24 antigen Allow for earlier diagnosis than serology alone Currently recommended by CDC for routine screening Still require confirmatory testing (Western blot no longer good option)
12 Laboratory Testing Recommendations for the Diagnosis of HIV, Updated Recommendations, Centers of Disease Control and prevention, June 2014
13 Detects all immunoglobulin classes to HIV-1 and HIV-2 Detects p24 expressed by HIV-1 and HIV-2 Increased sensitivity and specificity compared to many third generation assays Most are performed on large chemistry lab analyzers ADVIA Centaur <1 hour run time Abbott Architect <30min run time Bioplex 45 min run time Capable of differentiation between p24 and HIV1/2 antibodies Positive results require further confirmation
14 Laboratory Testing Recommendations for the Diagnosis of HIV, Updated Recommendations, Centers of Disease Control and prevention, June 2014
15 The Multispot Performed following positive antigen/antibody screen Second generation assay Detects only IgG antibody Steps Immobilized HIV-1 and HIV-2 antigens treated with patient serum After washing alkaline phosphatase labeled goat antihuman IgG is added Developer is added and positive test spot turn purple Control HIV-2 Peptide Recombinant HIV-1 HIV-1 Peptide = Nonreactive = HIV-1 Positive = HIV-1 Indeterminate = HIV-2 Positive
16 FDA approved supplemental HIV test Successor to the Multispot Multispot no longer in production by manufacturer Immunochromatographic assay Tests for antibodies against 4 HIV-1 proteins 2 HIV-2 proteins Results interpreted by an automated reader Helps prevent user error Sample Application HIV2 targets HIV1 targets Control
17 Laboratory Testing Recommendations for the Diagnosis of HIV, Updated Recommendations, Centers of Disease Control and prevention, June 2014
18 HIV RNA Detectable ~10 Days Following Infection NAAT is performed to detect acute cases HIV Antibodies Detectable ~20 Days Following Infection HIV Antigen Detectable ~15 Days Following Infection HIV Antibody Response Expands Nucleic Acid Detection Test Positive Patient may have acute HIV if fourth gen positive, differentiation assay negative Fourth Generation Antibody/Antigen Assay Positive Third Generation Antibody Assay Positive Western Blot Positive
19 Currently only one FDA approved molecular test is available for the diagnosis of HIV-1 Aptima HIV-1 RNA Detects viral RNA using transcription mediated amplification Quantitative tests are FDA approved for monitoring only But more readily available than qualitative tests Can be used as qualitative diagnostic tests following appropriate validation Important caveat: HIV-2 is not detected by these assays!
20 How Does This Algorithm Function? Laboratory Testing Recommendations for the Diagnosis of HIV, Updated Recommendations, Centers of Disease Control and prevention, June 2014
21 4 th Generation HIV-1/2 Antigen(AG)/Antibody(Ab)Combo, blood (n=10,536) 1% 99% HIV-1 Ab reactive: confirmed Reactive for HIV-1 (n=62) Reflexed to HIV-1 Viral Load 76% Reactive (n=82) Multispot for HIV- 1/HIV-2 Ab Differentiation (n=82) 22% Non-reactive for HIV-1/HIV-2 Ab (n=18) 0% Non-reactive (n=10,454) HIV-2 Ab reactive: confirmed Reactive for HIV-2 (n=0) 2% Reflexed HIV-1 Viral Load (n=17) 94% HIV-1 viral load Not Detected: Possible false positive screen (n=16) 6% No further testing. The final result is Nonreactive Undifferentiated recommend retesting or HIV-1 viral load (n=2) HIV-1 viral load Detected: consistent with acute or early HIV-1 infection (n=1)
22 Approximately 25% of antigen/antibody screens were false positives Is this too high??? A study of 10,014 life insurance applicants of low seroprevalence were tested by this algorithm 13 patients were positive on initial testing (85% false positives) A study of 51,935 Florida patients in a high seroprevalence setting were tested by the algorithm 1089 patients were positive on initial testing (7.2% false positives) Take home- Population sero-prevalence affects positive predictive value!
23 Conditions implicated with false positives Rheumatoid arthritis, lupus, Sjogren's and other autoimmune conditions Cross reacting viruses Pregnancy Chart review of patients with false positive screens (n=14) 7/14 patients were either pregnant (n=3) or had a documented autoimmune disorder (n=4) 2/14 had identified risk factors (IVDU) Both positive for HCV, though ultimately HIV negative Remaining five patients included Patient with alcoholic pancreatitis Patient with sepsis Patient with FUO that spontaneously resolved Patient with cystic fibrosis s/p lung transplant Patient with unknown medical history
24 Positive rapid antibody test, negative antigen/antibody screen Pregnant (associated with false positives) Can we say her rapid antibody test is a false positive?
25 Variety of different formats Some detect IgG only (second generation) Some detect IgG/IgM (third generation) Some detect IgG/IgM and p24 antigen (fourth generation) Advantages Easy to perform Results often in under 30 min Many are CLIA waived, so can be used POC Can use a variety of specimens (ie. saliva, blood, etc) Allows for immediate patient counseling
26 Test Chembio DPP HIV-1/2 Clearview COMPLETE HIV1/2 Clearview HIV1/2 STAT-PAK OraQuick ADVANCE Rapid HIV1/2 Antibody Test INSTI HIV-1/HIV-2 Antibody Test Uni-Gold Recombigen HIV1/2 Determine HIV1/2 AgAb Combo Test Detects HIV IgG antibody (second generation) HIV IgG/IgM antibody (third generation) HIV IgG/IgM antibody and antigen (fourth generation)
27 n= 7/32 n= 7/31 n= 8/33 n= 8/27 n= 11/33 n= 19/33 n= 25/33 n= 29/33 Sensitivity (%) Sensitivity in patients with positive nucleic acid amplification test and negative/indeterminate Western Blot Patel P, Bennett B, Sullivan T, Parker M M, Heffelfinger J D, Sullivan P S, and CDC AHI Study Group, Rapid HIV screening: Missed opportunites for HIV diagnosis and prevention. Journal of Clinical Virology 54(2012) 42-47
28 Western blot or IFA was previously recommended to confirm rapid tests This was because certain rapid tests were actually more sensitive than in-lab immunoassays This has changed with the fourth generation testing Fourth generation in-lab tests are more sensitive and specific than currently available rapid tests (even rapid fourth generation tests)
29 Fourth gen antigen/antibody tests have much greater sensitivity than third gen tests (should ALWAYS be positive if third gen test is true positive) HIV RNA Detectable ~10 Days Following Infection HIV Antibodies Detectable ~20 Days Following Infection HIV Antigen Detectable ~15 Days Following Infection HIV Antibody Response Expands Fourth Generation Antibody/Antigen Assay Positive Third Generation Antibody Assay Positive
30 Any reactive rapid antigen test should be tested by the fourth generation algorithm starting at the beginning Supplemental testing is NOT required for any patients positive by rapid antigen, and negative by fourth generation The role of the rapid test is to screen for those who should get fourth generation testing
31 Advantages Allow for bedside diagnosis Allow for same visit counseling Allow for taking the testing to the patient Is rapid HIV testing appropriate in the hospital? It depends! If your hospital is able to provide same visit in-lab testing probably not
32 Adapted from: Reactive rapid HIV antibody test (3 rd or 4 th generation) HIV-1/2 antigen/antibody combination immunoassay (preferred screen) (+) HIV-1/HIV-2 antibody differentiation immunoassay (-) Negative for HIV-1 and HIV-2 antibodies and p24 antigen HIV-1 (+) HIV-2 (-) HIV-1 antibodies detected HIV-1 (-) HIV-2 (+) HIV-2 antibodies detected HIV-1 (+) HIV-2 (+) HIV antibodies detected HIV-1 (-) or indeterminate HIV-2 (-) HIV-1 RNA* HIV-1 infection HIV-2 infection Cannot differentiate HIV-1 and HIV-2. Consider molecular testing or testing serology at later date HIV-1 RNA (+) Acute HIV-1 infection HIV-1 RNA (-) Negative for HIV-1
33 Proper HIV testing stewardship is a laboratory responsibility Challenges to consider Result reporting/communication Specimen requirements Assuring follow-up testing is performed Algorithmic testing should be developed in collaboration with the entire patient care team!!!
34 OB patient with positive rapid, negative in-lab fourth gen assay No further testing was performed Patient was told she did not have HIV In retrospect, physician did not know which HIV test to order It was discussed with OB providers that the inlab fourth gen is nearly as fast though more accurate Rapid HIV testing is no longer performed in this area
35
36 Treatment requires combination of highly active antiretroviral drugs (HAART) Nucleotide reverse transcriptase inhibitors (NRTIs) Non-nucleotide reverse transcriptase inhibitors (NNRTIs) Protease inhibitors Fusion inhibitors CCR5 entry inhibitors Integrase inhibitors Nature Reviews Drug Discovery 6, (Dec 2012)
37 Reverse transcriptase is prone to errors HIV lacks a proofreading enzyme 1 random mutation occurs per site per day Patients must be on multidrug therapy Patients on ineffective combination therapy will rapidly develop drug resistance Zidovudine studies show nearly 100% resistance in 6 months Patients need to be carefully monitored for resistance
38 Derived from Health and Human services working group for HIV guidelines CD4 Useful measurement of immune status at diagnosis Conveys urgency of starting treatment for HIV and opportunistic infections Viral load Useful predictor of disease progression at diagnosis Useful marker of disease progression after the start of therapy
39 Measure immediately before treatment and 2-8 weeks later 2 log copies/ml decrease in viral load after first 2-3 months indicates treatment response Monitor every 3-4 months to ensure response Treatment goal: undetectable by week log copies/ml difference is clinically significant (threefold change) Biologic variation 0.3 log Assay variation 0.2 log
40 Only detect HIV-1 Earlier developed assays used a variety of technologies Conventional reverse transcription PCR Branched DNA signal amplification Nucleic Acid Sequence Based Amplification More recent viral load assays use real time PCR Signal generated during amplification process by fluorescent probes
41 Less manipulation of specimens so less chance for contamination Highly automated for high throughput Higher sensitivity for recombinant forms and less common genotypes Lower levels of detection (40 and 20 copies/ml)
42 March 2008 Clinical Infectious Disease publication 1387 patients visited clinic March thru June 876 had been followed frequently (ie seen every 1-3 months) and had previously negative viral loads by Amplicor Monitor system (LOD 50 copies/ml) Switched to CAPTAQ (RealTime PCR) HIV viral load was >50 copies/ml in 253 patients (28.9%) Gatanaga et al, Detection of HIV Type 1 Load by the Roche Cobas Tapman Assay in Patients with Viral Loads Previously Undetectable by the Roche Cobas Amplicor Monitor, CID, Vol48, pp , 2009
43 Is next generation viral load testing too sensitive? Added cost Over-interpretation of drug failure Psychological distress Are all positive results significant?
44 Defined by the 2014 Panel on Antiretroviral Guidelines for Adults and Adolescents (Department of Health and Human Services) Viral loads transiently detectable at low levels (typically <400 copies/ml) May be seen in patients with transient infections Recommended NOT to check viral loads when patients are acutely ill May be seen transiently after vaccination for influenza, tetanus, or pneumococcus
45 All patients at initiation of treatment Patients with true virologic failure and HIV RNA levels >1,000 copies/ml If viral load >500 but <1,000 testing may be unsuccessful, but should be considered Patients with suboptimal initial response to therapy Failure to completely suppress viral load initially
46 Genotypic methods Two FDA approved assays for the sequencing of reverse transcriptase and protease genes Lab developed assays for the sequencing of other genes of concern (ie. integrase) PR RT
47 Phenotypic methods Able to test more drugs than those tested by commercial genotype assays Only performed at commercial laboratories The amount of drug necessary to inhibit 50% and 90% is reported
48 Tropism assays HIV binds either CCR5 or CXCR-4 as a co-receptor for cell entry Miravaroc is a CCR5 entry inhibitor and only effective when virus is CCR5 tropic The ability of cloned vector to infect CCR5 positive cell lines and CXCR-4 positive cell lines is measured CCR5 Positive CXCR-4 Positive Growth???
49 Patient Isolate Amplify and Sequence Compare to database of known mutations Limitations of all Methods Genotyping Phenotyping Tropism Assays Must have adequate viral load ( cp/ml) Resistant clone must comprise 20-30% of the viral population Patient Isolate Amplify and clone viral nucleic acid into vector Grow new virus in presence of different antiviral concentrations Patient Isolate Amplify and clone viral nucleic acid into vector Grow new virus in cell lines expressing either CCR5 or CXCR-4 Pro: Easy to perform Con: Limited amount of drugs detected Pro: Able to test many drugs Con: Laborious and expensive
50 HIV molecular testing plays an important role in the diagnosis of acute HIV HIV viral load should be monitored during treatment to assess for drug resistance Sustained or large increases in HIV viral load should be followed up with resistance testing While genotyping is most common, several different resistance detection assays are available All forms of HIV resistance testing have limitations which should be considered prior to ordering
51
52 Rapid qualitative molecular testing Currently only one FDAapproved molecular test is available for diagnosis Cepheid Xpert HIV-1 Qualitative test has been CE marked and marketed abroad 90 minute run time and amenable to near-poc
53 Bioplex (5 th generation HIV testing) Tests separately and differentiates HIV 1 ab, HIV 2 ab, and p24 Acceptable 4 th gen screening assay though technically also an HIV1/2 differentiation assay Could change testing algorithm dramatically
54 THEORETICAL!!!! HIV-1 AB -, p24 - Negative HIV-1 AB +, p24 - HIV-1 AB -, p24 + Additional testing required What should be used for confirmatory testing? 5 th Generation Assay Is this specific HIV-1 AB +, p24 + Positive enough to establish a diagnosis? More data is needed regarding the performance of the Bioplex
55 Measuring drug resistance in archived viral DNA integrated into CD4 T cells In theory this should allow resistance testing on patients with suppressed viral loads Data is currently conflicting regarding utility Free virus CD4+ Lymphocyte
56 Used to detect small resistance populations amongst circulating virus Limit of detection approximately 1% Many mutations are indeed low abundance Simon et al. Low-Abundance Drug-Resistant Viral Variants in Chronically HIV- Infected, Antiretroviral Treatment-Naïve Patients Significantly Impact Treatment Outcomes, JID 2009:199 (1 March)
57 Minority Variant % Virologic Failure Total Hazard Ratio Minority Variant No Minority Variant Minority Variant No Minority Variant (95% CI) < ( ) < ( ) Li et al. Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI- Based Antiretroviral Treatment Failure. JAMA, April 6, 2011 V Systematic review published in JAMA -Compiled pooled outcome data from 10 different studies -Examining outcomes in patients with minority variants receiving treatment Resistant minority variants likely are clinically significant and their detection may allow for the better management of patients with HIV
58
59 25 year old male with fever, malaise, and history of IVD HIV serology screen (4 th generation ELISA) Fourth generation ELISA positive, multispot test negative HIV RNA PCR (quant or qual) HIV qualitative PCR positive HIV quantitative PCR and resistance testing
60 Patient has no detectable baseline drug resistance. Initial viral load is 100,000 copies per ml, repeat viral load two days later is 200,000 copies/ml No testing at this time, wait 2 weeks/months Patient viral load undetectable within two years. Five years later patient found to have viral load of 100 copies/ml Recheck one month later (could be blip) One month later viral load at 1000 copies/ml Resistance testing ordered
61
Learning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016
New HIV Testing Algorithm from CDC ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Learning Objectives Following attendance and review of material provided, attendees will be able to: 1. Describe the new
More informationHIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC)
HIV Update in Laboratory Testing Patricia Slev, PhD, D(ABCC) Objectives Explain the advances in HIV diagnostics, including fourth generation Ag/Ab combination HIV screening assays Describe the new CDC
More informationNew HIV Tests and Algorithm: A change we can believe in
New HIV Tests and Algorithm: A change we can believe in Esther Babady, PhD, D (ABMM) Memorial Sloan-Kettering Cancer Center New York, New York Learning Objectives After this presentation you should be
More informationHIV Testing Technology and the Latest Algorithm
HIV Testing Technology and the Latest Algorithm David Warshauer, PhD, D(ABMM) Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene HIV Testing has changed over time Patients with
More informationThe Latest in HIV Tests: What Do the Results Mean?
The Latest in HIV Tests: What Do the Results Mean? Bernard M. Branson MD Principal Consultant, Scientific Affairs LLC Atlanta, Georgia Objectives At the end of this workshop, participants will be able
More informationHIV Test Technologies, Best Practices, and New Algorithm. Jenny R. McFarlane DSHS HIV Prevention and Care Branch
HIV Test Technologies, Best Practices, and New Algorithm Jenny R. McFarlane DSHS HIV Prevention and Care Branch Testing History 1985 1 st Gen HIV-1 IA 1987 HIV-1 WB 1990 HIV-2 IA HIV-1 IA DBS 1991 2 nd
More informationAdvantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform*
Advantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform* HIV immunoassays grouped by generation, platform, and CLIA complexity + Advantages
More information1 st and 2 nd Generation EIA
HIV Diagnostic Tests Bernard M. Branson, M.D. Associate D irector for Laboratory D iagnostics Division of HIV/AIDS Prevention Centers for D isease Control & Prevention The views expressed in this presentation
More informationOverview of HIV Testing Practices and Technology
Overview of HIV Testing Practices and Technology 2019 HIV Diagnostics Conference March 25 th, 2019 Michele Owen, Ph.D National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease
More information2018 HIV and HCV Diagnostic Testing Survey
2018 HIV and HCV Diagnostic Testing Survey This survey is designed to capture the 2017 HIV and HCV testing practices in state and local public health laboratories (PHL). The results of the survey will
More informationNew Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention
New Generation of Nucleic Acid Testing Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention Percentage (%) Persons Living with Diagnosed or Undiagnosed HIV Infection
More informationSupplementary Online Content
Supplementary Online Content Peters PJ, Westheimer E, Cohen S, et al. Screening yield of HIV antigen/antibody combination and pooled HIV RNA testing for acute HIV infection in a high-prevalence population.
More informationComplicated viral infections
Complicated viral infections Clinical case discussion Diagnostic dilemmas NSW State Reference Laboratory for HIV St Vincent s Hospital Sydney Diagnostic dilemmas Indeterminate or discordant serology (western
More informationHIV Diagnostic Testing
In The name of God HIV Diagnostic Testing By : Dr. Shahzamani PhD of Medical virology Purpose of HIV Testing To identify asymptomatic individuals To diagnose HIV infection in those who practice high risk
More informationA Summary of Clinical Evidence
A Summary of Clinical Evidence Supporting the use of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test to assist in the diagnosis of Human Immunodeficiency Virus (HIV) TAP HERE TO SEE THE PRODUCTS Table
More informationRoutine HIV Testing Community of Practice Session #2
Routine HIV Testing Community of Practice Session #2 Presenters: Denver Prevention Training Center Broward Community & Family Health Centers, Inc. 20 March 2016 Communities of Practice Routine HIV Testing
More informationMicropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ
www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons
More informationPoint-of-care HIV testing
Point-of-care HIV testing Joanne Stekler, MD MPH Associate Professor University of Washington December 5, 2016 Disclaimer: The findings and conclusions in this presentation are those of the author(s) and
More informationARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S.
ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. Catherine Brennan, Ph.D. Research Fellow Infectious Diseases Research Abbott Diagnostics 1 Agenda ARCHITECT HIV Ag/Ab Combo Assay What
More informationRNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis
RNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis 1 B R E N D A N M C M U L L A N I N F E C T I O U S D I S E A S E S, S Y D N E Y C H I L D R E N S H O S P I T A L S C H O O L O F W O
More informationDiagnostic Tests for HIV
Mountain West AIDS Education and Training Center Diagnostic Tests for HIV David Spach, MD Principal Investigator, Mountain West AETC Professor of Medicine, University of Washington Last Updated: June 22,
More informationDiagnosis and Management of Acute HIV
Diagnosis and Management of Acute HIV A New HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV, this committee
More informationAdventures in Discordance- HIV Testing
Anne Gaynor, PhD On behalf of Monica M. Parker, PhD Director, Bloodborne Viruses Laboratory Wadsworth Center, NYSDOH Adventures in Discordance- HIV Testing HIV Laboratory Testing Algorithm HIV-1/2 antigen/antibody
More informationINTEGRATING HIV AND HCV TESTING
INTEGRATING AND HCV TESTING OVERVIEW Increasingly health departments (HDs) are seeking new strategies to improve the productivity and yield of testing and linkage programs, expand availability of and access
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationOpportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests
Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests Ann Winters, MD Medical Director, Viral Hepatitis Program, Bureau of Communicable Disease, New York City Department of Health and Mental
More informationObjectives. Seven days of separation. Clinical situation a transplant. The Donor COOMBS MD PHD 1. Laboratory Diagnosis & Monitoring of HIV Infection
Laboratory Diagnosis & Monitoring of HIV Infection An Introduction to Diagnostic HIV Testing Robert W Coombs MD, PhD, FRCPC Professor, Departments of Laboratory Medicine & Medicine University of Washington,
More informationEvolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention
Evolution of HIV Diagnostics and Goals for the 2010 Conference Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics CDC Division of HIV/AIDS Prevention Evolution or other influences like
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationAdvaMedDx Value Assessment Framework in Practice
AdvaMedDx Value Assessment Framework in Practice Application of the Comprehensive Assessment of the Value of Diagnostic Technologies Framework to Abbott s 4th Generation ARCHITECT HIV Antigen/Antibody
More informationDiagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know
Diagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know Carolyn K. Burr, EdD, RN Co-Clinical Director Deputy Director François-Xavier Bagnoud Center December 17 th, 2013
More informationCh 18 Infectious Diseases Affecting Cardiovascular and Lymphatic Systems
Ch 18 Infectious Diseases Affecting Cardiovascular and Lymphatic Systems Highlight Disease: Malaria World s dominant protozoal disease. Four species of Plasmodium: P. falciparum (malignant), P. vivax (begnin),
More informationHIV: 2009 DIAGNOSTIC SURVEY FACING NEW CHALLENGES
ISSUES IN BRIEF: MEMBER SURVEY OF HIV ASSAY USE ASSOCIATION OF PUBLIC HEALTH LABORATORIES MARCH 2010 HIV: 2009 DIAGNOSTIC SURVEY FACING NEW CHALLENGES Twenty years ago, the Association of Public Health
More informationThe Evolving Landscape of HIV Prevention and Diagnosis
The Evolving Landscape of HIV Prevention and Diagnosis Jenny R. McFarlane Texas Department of State Health Services HIV/STD/TB/Viral Hepatitis Unit Is it okay if we just talk? NHAS: A Call to ACT Reduce
More informationHIV 101: Fundamentals of HIV Infection
HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able
More informationImmunologic Methods in Diagnosis of HIV Infection. Tehran Medical Sciences Branch, Islamic Azad
Immunologic Methods in Diagnosis of HIV Infection M Parsania, Ph.D. Tehran Medical Sciences Branch, Islamic Azad University Retroviridae Retroviruses (family Retroviridae) id ) are enveloped, single stranded
More informationHUMAN IMMUNODEFICIENCY VIRUS (HIV) NON-IMMEDIATE NOTIFICATION STD PROGRAM. Version
1 HUMAN IMMUNODEFICIENCY VIRUS (HIV) NON-IMMEDIATE NOTIFICATION STD PROGRAM Event Name: Event Time Period: ADULT HIV 900 (AIDS.gov 12/31/2015) HIV Lifelong HIV (human immunodeficiency virus) is a retrovirus
More informationCAPACITY OF THE HEALTHCARE SYSTEM TO INCREASE PROVISION OF HIV TESTING
Institute of Medicine (2010) CAPACITY OF THE HEALTHCARE SYSTEM TO INCREASE PROVISION OF HIV TESTING Workshop on the Capacity of the Healthcare System to Identify and Provide Care for Individuals with HIV/AIDS
More informationHIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary
More informationTrends in molecular diagnostics
Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling
More information2006 HIV Diagnostics Survey
Public Health Laboratory Issues in Brief: 2006 HIV Diagnostics Survey Association of Public Health Laboratories November 2007 Background Nearly 20 years ago, the Association of Public Health Laboratories
More informationHIV Guideline Sakchai Dettrairat
HIV Guideline 2016 Sakchai Dettrairat Division of Clinical Immunology Department of Medical Technology Faculty of Associated Medical Sciences Chiang Mai University Appearance of HIV markers in early HIV
More informationDiagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)
Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves
More informationHEALTH. Re: Interim Guidelines for Laboratories on the use of a new Diagnostic Testing Algorithm for Human Immunodeficiency Virus (HIV) Infection
===========ir ~~!!~~fk li=:='========= Nirav R. Shah, M.D., M.P.H. Commissioner May 16, 2013 HEALTH Sue Kelly Executive Deputy Commissioner Re: Interim Guidelines for Laboratories on the use of a new Diagnostic
More informationSP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World
MIT OpenCourseWare http://ocw.mit.edu SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World Spring 2009 For information about citing these materials or our
More informationClinical Education Initiative TESTING FOR HIV AND HCV: WHAT S CURRENT AND WHAT S COMING. Bernard M.
Clinical Education Initiative Support@ceitraining.org TESTING FOR HIV AND HCV: WHAT S CURRENT AND WHAT S COMING Bernard M. Branson, MD 1/23/2018 Testing for HIV and HCV: What s Current and What s Coming
More informationObstetrics and HIV An Update. Jennifer Van Horn MD University of Utah
Obstetrics and HIV An Update Jennifer Van Horn MD University of Utah Obstetrics and HIV Perinatal transmission Testing Antiretroviral therapy Antepartum management Intrapartum management Postpartum management
More informationDiagnosing HIV Infection AMNERIS E. LUQUE, M.D. PROFESSOR OF MEDICINE/INFECTIOUS DISEASES MEDICAL DIRECTOR, PARKLAND HIV SERVICES
Diagnosing HIV Infection AMNERIS E. LUQUE, M.D. PROFESSOR OF MEDICINE/INFECTIOUS DISEASES MEDICAL DIRECTOR, PARKLAND HIV SERVICES Disclosures None Objectives 1. Outline the CDC recommendations for HIV
More informationHIV testing has significantly improved
HIV testing: an update By Nicola Zetola, MD, and Jeffrey D. Klausner, MD, MPH HIV testing has significantly improved since the first diagnostic test in 1985. Increased understanding of HIV transmission
More informationThe Application of molecular POCT for Influenza and Group A Strep Detection
The Application of molecular POCT for Influenza and Group A Strep Detection Gregory J. Berry, Ph.D., D(ABMM) Assistant Professor, Pathology and Laboratory Medicine Zucker School of Medicine at Hofstra/Northwell
More informationHIV Serology Quality Assessment Program Summary for Panel HIVS Oct22
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091650 Age 49 Years Gender Male 29/8/2017 120000AM 29/8/2017 100248AM 29/8/2017 105306AM Ref By Final HEATITIS, VIRAL, COMREHENSIVE ANEL HEATITIS A ANTIBODY (ANTI
More informationACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS
ACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS Acquired immunodeficiency syndrome (AIDS ) is an infectious disease caused by a retrovirus, the human immunodeficiency virus(hiv). AIDS is
More informationAn Evaluation of Qualitative HIV-2 RNA Referral Testing
An Evaluation of Qualitative HIV-2 RNA Referral Testing Linda M. Styer, Anne Gaynor, Laura Wesolowski, Steve Ethridge and Monica M. Parker Wadsworth Center, NYSDOH; APHL; Division of HIV/AIDS Prevention,
More informationSusanne Norris Zanto, MPH, MLS (ASCP) CM, SM Montana Public Health Laboratory
Susanne Norris Zanto, MPH, MLS (ASCP) CM, SM Montana Public Health Laboratory Describe the challenges in syphilis diagnostics Present two testing algorithms Non-treponemal test as initial screen Treponemal
More informationAccuSet HIV-1/2 Performance Panel
OVERVIEW AccuSet HIV-1/2 (0800-0380) is a 13-member validation panel of undiluted, naturally occurring plasma samples (1 vial per member, 1.0 ml per vial). Panel members represent bleeds from multiple
More informationMolecular Diagnosis Future Directions
Molecular Diagnosis Future Directions Philip Cunningham NSW State Reference Laboratory for HIV/AIDS & Molecular Diagnostic Medicine Laboratory, SydPath St Vincent s Hospital Sydney Update on Molecular
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationRama Nada. - Malik
- 2 - Rama Nada - - Malik 1 P a g e We talked about HAV in the previous lecture, now we ll continue the remaining types.. Hepatitis E It s similar to virus that infect swine, so its most likely infect
More informationHuman Immunodeficiency Virus
Human Immunodeficiency Virus Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Viruses and hosts Lentivirus from Latin lentis (slow), for slow progression of disease
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationHIV Testing. Susan Tusher, LMSW Program Coordinator The Kansas AIDS Education and Training Center
HIV Testing Susan Tusher, LMSW Program Coordinator The Kansas AIDS Education and Training Center The Number of Persons in the US Living with HIV Continues to Increase Over 1 Million people are estimated
More informationLESSON 4.6 WORKBOOK. Designing an antiviral drug The challenge of HIV
LESSON 4.6 WORKBOOK Designing an antiviral drug The challenge of HIV In the last two lessons we discussed the how the viral life cycle causes host cell damage. But is there anything we can do to prevent
More informationA Case of False-Positive Test Results in a Pregnant Woman of Unknown HIV Status at Delivery
A Case of False-Positive Test Results in a Pregnant Woman of Unknown HIV Status at Delivery Pascale Akl, MD, 1 Kenneth E. Blick, PhD 1* Lab Med Spring 2014;45:259-263 DOI: 10.1309/LMAAGVXK05LUWOQN ABSTRACT
More informationPROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV
PROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV Madhuri Lad, DO, FACOI, AAHIVS Clinical Assistant Professor OSU Department of Internal Medicine OBJECTIVES Demographics Definitions Diagnosis
More informationHIV and PEP. LTC Rose Ressner WRNMMC ID staff Oct 2014 UNCLASSIFIED
HIV and PEP LTC Rose Ressner WRNMMC ID staff Oct 2014 UNCLASSIFIED Disclaimer The views expressed in this presentation are those of the speaker and do not reflect the official policy of the Department
More informationHIV Drug Resistance. Together, we can change the course of the HIV epidemic one woman at a time.
HIV Drug Resistance Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is Resistance? HIV drugs are designed to keep the amount of HIV virus
More informationQUANTITATIVE HIV RNA (VIRAL LOAD)
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HIV RNA (VIRAL LOAD) Policy Number: PDS - 008 Effective Date: October
More informationHIV Basics: Clinical Tests and Guidelines
HIV Basics: Clinical Tests and Guidelines ACTHIV 2010 Zelalem Temesgen MD Mayo Clinic Topics Baseline laboratory evaluation Laboratory monitoring through the continuum of care Patients not on antiretroviral
More informationThe ABC s (and D & E s) of the Viral Hepatitides Part 2 DIAGNOSTIC TESTS 3/7/2013
The ABC s (and D & E s) of the Viral Hepatitides Part 2 Thomas Novicki PhD DABMM Clinical Microbiologist Division of Laboratory Medicine novicki.thomas@marshfieldclinic.org Objectives 2 1. Explain the
More informationEDITORIAL Issue Fifteen, August 2003
EDITORIAL, August 2003 The featured article in this edition is Laboratory diagnosis for infection with Human Immunodeficiency virus (HIV) by Dr John Vivian Wells and Richard Allen. The authors combined
More informationImmunodeficiencies HIV/AIDS
Immunodeficiencies HIV/AIDS Immunodeficiencies Due to impaired function of one or more components of the immune or inflammatory responses. Problem may be with: B cells T cells phagocytes or complement
More information5. Over the last ten years, the proportion of HIV-infected persons who are women has: a. Increased b. Decreased c. Remained about the same 1
Epidemiology 227 April 24, 2009 MID-TERM EXAMINATION Select the best answer for the multiple choice questions. There are 60 questions and 9 pages on the examination. Each question will count one point.
More informationHIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg
HIV viral load testing in the era of ART Christian Noah Labor Lademannbogen, Hamburg 1 Life expectancy of patients on ART Data from the UK Collaborative HIV Cohort (UK CHIC) Requirements: Early diagnosis
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091606 Age 24 Years Gender Male 30/8/2017 92800AM 30/8/2017 94631AM 31/8/2017 90306AM Ref By Final HEATITIS A & B VIRUS EVALUATION HEATITIS A ANTIBODY (ANTI HAV),
More informationFig. 1: Schematic diagram of basic structure of HIV
UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL SEMINAR HIV & AIDS: An Overview What is HIV?
More informationCase Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.
Case Study Dr Sarah Sasson Immunopathology Registrar HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital Case 1: Case 1: 45F in Cameroon Cameroon HIV+ Presents with cutaneous
More informationTEST REQUEST INFORMATION- VIROLOGY
Chlamydia/ Gonorrhea Nucleic Acid Amplification VC75 Qualitative Nucleic Acid Amplification SPECIMEN: Genital swab or first catch urine CONTAINER:GEN-PROBE APTIMA 2 Combo swab transport tube or urine transport
More informationHIV Drug Resistance: An Overview
Human Journals Review Article October 2015 Vol.:1, Issue:1 All rights are reserved by Suraj Narayan Mali et al. HIV Drug Resistance: An Overview Keywords: HIV drug resistance mechanism, Antiretroviral
More information2017 HIV AND HCV DIAGNOSTICS SURVEY REPORT
207 HIV AND HCV DIAGNOSTICS SURVEY REPORT MARCH 209 Table of Contents Background...3 Methods...3 Workforce...3 HIV Assay Utilization...4 Turnaround Time...6 Testing Volume and Specimen Types...7 Testing
More informationAPHL/CDC HIV Demonstration Project Demonstration Project for HIV Nucleic Acid Testing (NAT) Referral Updated: January 2018
APHL/CDC HIV Demonstration Project Demonstration Project for HIV Nucleic Acid Testing (NAT) Referral Updated: January 2018 Shipping and Submission Instructions Thank you for participating as a submitting
More informationTechnical Bulletin No. 161
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 161 cobas 6800 HIV-1 Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations
More informationHIV/HCV Screening in 2015: Where Are We Now? Bernard M. Branson, M.D.
HIV/HCV Screening in 2015: Where Are We Now? Bernard M. Branson, M.D. Disclosures Dr. Branson has no financial interests to disclose. Terminology Diagnostic testing: performing a test based on clinical
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091608 Age 26 Years Gender Female 30/8/2017 92900AM 30/8/2017 94717AM 31/8/2017 90216AM Ref By Final HEATITIS ACUTE VIRUS CONFIRMATION HEATITIS A ANTIBODY (ANTI HAV),
More informationImmunodeficiency. (2 of 2)
Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related
More informationIntegrating HIV Screening Into
MaxiMizing Third ParTy reimbursement for hiv TesTing Integrating HIV Screening Into Title X Services IntroductIon HIV screening services are a core family planning service, and all individuals aged 13-64
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationModule 3: Overview of HIV Testing Technologies
Module 3: Overview of HIV Testing Technologies Purpose Pre-requisite Modules Module Time Learning Objectives To provide the participants with a basic knowledge of HIV testing and how HIV rapid test results
More informationHIV INFECTION: An Overview
HIV INFECTION: An Overview UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL MBBS II SEMINAR VJ
More informationHIV Serology Quality Assessment Program Summary for Panel HIVSER 2018Apr19
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary
More informationAbility to Identify Acute HIV Infections from Surveillance Data Varies by Diagnostic Testing Algorithm
Ability to Identify Acute HIV Infections from Surveillance Data Varies by Diagnostic Testing Algorithm Laurie Linley, MPH; Anne H. Peruski, MPH, PhD; Richard M. Selik, MD; Kevin P. Delaney, MPH, PhD; Alexandra
More informationObjectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care.
1:30 2:30pm HIV Update SPEAKER Gordon Dickinson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Gordon Dickinson, MD, has no financial relationships
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationNew CT/GC Tests. CDC National Infertility Prevention Project Laboratory Update Region II May 13-14, 2009
CDC National Infertility Prevention Project Laboratory Update Region II May 13-14, 2009 Richard Steece, Ph.D., D(ABMM) DrRSteece@aol.com New CT/GC Tests New Nucleic Acid Amplification Tests (NAATs) for
More informationHepatitis C Best Practice Guidelines For Local Health Departments
Hepatitis C Best Practice Guidelines For Local Health Departments LHDs are responsible for investigating and reporting all physician reported cases of acute hepatitis C (HCV). For clients known to have
More information